AURA
Closed
Aura Biosciences Inc
6.26
0.00 (0.00%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 6.26
Day's Range: 6.07 - 6.42
Send
sign up or login to leave a comment!
When Written:
9.28
Aura Biosciences Inc is a clinical-stage biopharmaceutical company that is focused on developing and commercializing therapies for the treatment of cancer. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Aura Biosciences is developing a novel class of therapies called viral nanoparticle conjugates (VNCs) that are designed to selectively target and destroy cancer cells while sparing healthy tissue. The company's lead product candidate, AU-011, is a VNC that is being developed for the treatment of ocular melanoma, a rare and aggressive form of eye cancer.
AU-011 is currently being evaluated in a Phase 2 clinical trial, and Aura Biosciences has received fast track designation from the US Food and Drug Administration (FDA) for the development of the drug. The company has also received funding from the National Cancer Institute and the National Eye Institute to support the development of AU-011.
In addition to AU-011, Aura Biosciences is also developing VNCs for the treatment of other types of cancer, including bladder cancer and glioblastoma. The company has partnerships with several leading academic institutions and research organizations to support its research and development efforts.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Aura Biosciences is developing a novel class of therapies called viral nanoparticle conjugates (VNCs) that are designed to selectively target and destroy cancer cells while sparing healthy tissue. The company's lead product candidate, AU-011, is a VNC that is being developed for the treatment of ocular melanoma, a rare and aggressive form of eye cancer.
AU-011 is currently being evaluated in a Phase 2 clinical trial, and Aura Biosciences has received fast track designation from the US Food and Drug Administration (FDA) for the development of the drug. The company has also received funding from the National Cancer Institute and the National Eye Institute to support the development of AU-011.
In addition to AU-011, Aura Biosciences is also developing VNCs for the treatment of other types of cancer, including bladder cancer and glioblastoma. The company has partnerships with several leading academic institutions and research organizations to support its research and development efforts.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!